ACSS2 inhibitors currently in Phase I study for metastatic tumors (NCT04990739) or a transition state ACSS2 mimetic [53, 56] may be better suited for a full apoptotic restoration to prevent stroma-dependent protection. Here, ACSS2 is linked to metastatic neoplasm.